journal article·2023-03Open access

Natural killer cell-mimicking nanomaterial for overcoming the multidrug resistance of tumor via cascade catalysis

Min-Jie Li, Fan Gao, Qian-Xiao Huang, Jun Feng, Chuan-Jun Liu, Shu-Ling Gong, Xian-Zheng Zhang

Science China Materials· Volume 66· Issue 3

Abstract

由于优异的治疗效果, 化疗被广泛应用于癌症的早期治疗. 但在肿瘤化疗过程中, 多药耐药(MDR)的出现, 成为了抗肿瘤化疗的首要障碍. 本文提出了一种仿生自然杀伤(NK)细胞的纳米粒子(DMLN), 通过级联催化反应促进阿霉素(DOX)进入肿瘤细胞以克服MDR. DMLN是通过将NK细胞膜与负载有DOX和乳酸氧化酶(LOX)的中空二氧化锰纳米粒子复合来实现的. 在肿瘤微环境中, DMLN可以降解并释放Mn2+, 然后发生类Fenton反应, 在肿瘤细胞周围产生大量羟基自由基(·OH). ·OH会增加肿瘤细胞膜的通透性, 促进DOX进入肿瘤细胞, 进而提高细胞内DOX的浓度以克服MDR. 此外, 由于NK细胞膜的包覆,DMLN具有良好的肿瘤血液循环和肿瘤聚集能力. 体外和体内实验显示, DMLN对多药耐药肿瘤具有显著的抗肿瘤作用. 这种NK细胞模拟策略为克服肿瘤治疗中的MDR提供了一种新的思路.
Source: expertdata · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Immune Cell Function and Interaction

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (42)

Show source-provided references
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71: 209–24910.3322/caac.21660 ↗
2. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med, 2018, 378: 1976–198610.1056/NEJMoa1716078 ↗
3. Jia Q, Wu W, Wang Y, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun, 2018, 9: 536110.1038/s41467-018-07767-w ↗
4. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med, 2013, 368: 987–99810.1056/NEJMoa1209825 ↗
5. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375: 1823–183310.1056/NEJMoa1606774 ↗
6. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 2015, 373: 23–3410.1056/NEJMoa1504030 ↗
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12: 252–26410.1038/nrc3239 ↗
8. Prudowsky ZD, Yustein JT. Recent insights into therapy resistance in osteosarcoma. Cancers, 2020, 13: 8310.3390/cancers13010083 ↗
9. Pluchino KM, Hall MD, Goldsborough AS, et al. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resistance Updates, 2012, 15: 98–10510.1016/j.drup.2012.03.002 ↗
10. Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer, 2013, 13: 714–72610.1038/nrc3599 ↗
11. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer, 2002, 2: 48–5810.1038/nrc706 ↗
12. Li LY, Guan Y, Chen XS, et al. DNA repair pathways in cancer therapy and resistance. Front Pharmacol, 2020, 11: 62926610.3389/fphar.2020.629266 ↗
13. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer, 2012, 12: 587–59810.1038/nrc3342 ↗
14. Shahar N, Larisch S. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resistance Updates, 2020, 52: 10071210.1016/j.drup.2020.100712 ↗
15. Tsialtas I, Georgantopoulos A, Karipidou ME, et al. Anti-apoptotic and antioxidant activities of the mitochondrial estrogen receptor beta in N2A neuroblastoma cells. Int J Mol Sci, 2021, 22: 762010.3390/ijms22147620 ↗
16. Dong J, Qin Z, Zhang WD, et al. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resist Updates, 2020, 49: 10068110.1016/j.drup.2020.100681 ↗
17. Yu J, Zhou P, Asenso J, et al. Advances in plant-based inhibitors of P-glycoprotein. J Enzyme Inhibit Med Chem, 2016, 31: 867–88110.3109/14756366.2016.1149476 ↗
18. Wang C, Sun PF, Fan QL. NIR-II fluorescence probe based on polyamidoamine dendrimers for immunotherapy as antigen carrier. Acta Polym Sin, 2022, 53(02):174–184
19. Yang Q, Li C, Yu S, Wang Y, Hong M. Application of nanocarriers in co-loading siRNA and chemotherapeutic drugs to reverse multidrug resistance of tumor. Prog Chem, 2020, 33:1900–1932
20. Wang H, Liang Y, Yin Y, et al. Carbon nano-onion-mediated dual targeting of p-selectin and P-glycoprotein to overcome cancer drug resistance. Nat Commun, 2021, 12: 31210.1038/s41467-020-20588-0 ↗
21. Roque-Navarro L, Chakrabandhu K, de Leon J, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther, 2008, 7: 2033–204110.1158/1535-7163.MCT-08-0222 ↗
22. Eytan GD, Regev R, Oren G, et al. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem, 1996, 271: 12897–1290210.1074/jbc.271.22.12897 ↗
23. Zalba S, Ten Hagen TLM. Cell membrane modulation as adjuvant in cancer therapy. Cancer Treatment Rev, 2017, 52: 48–5710.1016/j.ctrv.2016.10.008 ↗
24. Casagrande N, Borghese C, Gabbatore L, et al. Analogs of a natural peptaibol exert anticancer activity in both cisplatin- and doxorubicin-resistant cells and in multicellular tumor spheroids. Int J Mol Sci, 2021, 22: 836210.3390/ijms22168362 ↗
25. Dai Y, Cai X, Shi W, et al. Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane. Amino Acids, 2017, 49: 1601–161010.1007/s00726-017-2453-y ↗
26. Kajarabille N, Latunde-Dada GO. Programmed cell-death by ferroptosis: Antioxidants as mitigators. Int J Mol Sci, 2019, 20: 496810.3390/ijms20194968 ↗
27. Yan B, Ai Y, Sun Q, et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol Cell, 2021, 81: 355–369.e1010.1016/j.molcel.2020.11.024 ↗
28. Ng CW, Li J, Pu K. Recent progresses in phototherapy-synergized cancer immunotherapy. Adv Funct Mater, 2018, 28: 180468810.1002/adfm.201804688 ↗
29. Guevara ML, Persano F, Persano S. Nano-immunotherapy: Overcoming tumour immune evasion. Semin Cancer Biol, 2021, 69: 238–24810.1016/j.semcancer.2019.11.010 ↗
30. Yang G, Phua SZF, Bindra AK, et al. Degradability and clearance of inorganic nanoparticles for biomedical applications. Adv Mater, 2019, 31: 180573010.1002/adma.201805730 ↗
31. Feng Q, Liu Y, Huang J, et al. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci Rep, 2018, 8: 208210.1038/s41598-018-19628-z ↗
32. Wehner R, Dietze K, Bachmann M, et al. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun, 2011, 3: 258–26310.1159/000323923 ↗
33. Cózar B, Greppi M, Carpentier S, et al. Tumor-infiltrating natural killer cells. Cancer Discov, 2021, 11: 34–4410.1158/2159-8290.CD-20-0655 ↗
34. Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res, 2015, 3: 575–58210.1158/2326-6066.CIR-15-0098 ↗
35. Huntington ND, Cursons J, Rautela J. The cancer-natural killer cell immunity cycle. Nat Rev Cancer, 2020, 20: 437–45410.1038/s41568-020-0272-z ↗
36. Li J, Zhen X, Lyu Y, et al. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. ACS Nano, 2018, 12: 8520–853010.1021/acsnano.8b04066 ↗
37. Zeng Z, Pu K. Improving cancer immunotherapy by cell membrane-camouflaged nanoparticles. Adv Funct Mater, 2020, 30: 200439710.1002/adfm.202004397 ↗
38. Lin H, Yang C, Luo Y, et al. Biomimetic nanomedicine-triggered in situ vaccination for innate and adaptive immunity activations for bacterial osteomyelitis treatment. ACS Nano, 2022, 16: 5943–596010.1021/acsnano.1c11132 ↗
39. Wu W, Pu Y, Yao H, et al. Microbiotic nanomedicine for tumor-specific chemotherapy-synergized innate/adaptive antitumor immunity. Nano Today, 2022, 42: 10137710.1016/j.nantod.2022.101377 ↗
40. Zheng Y, Han Y, Sun Q, et al. Harnessing anti-tumor and tumortropism functions of macrophages via nanotechnology for tumor immunotherapy. Exploration, 2022, 2: 2021016610.1002/EXP.20210166 ↗
41. Pan W, Ge Y, Yu Z, et al. A cancer cell membrane-encapsulated MnO2 nanoreactor for combined photodynamic-starvation therapy. Chem Commun, 2019, 55: 5115–511810.1039/C9CC01386E ↗
42. Liu W, Zou M, Qin S, et al. Recent advances of cell membrane-coated nanomaterials for biomedical applications. Adv Funct Mater, 2020, 30: 200355910.1002/adfm.202003559 ↗